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Discussion
Dr J. Coselli (Houston, Tex). Dr Roselli, congratulations on an
outstanding presentation. You and your colleagues have boldly
built upon a successful track record for the endovascular treatment
of abdominal aortic aneurysms and a growing experience with the
endovascular exclusion of juxtarenal and descending thoracic an-
eurysms with this innovative approach, allowing now for treatment
of those aneurysms traversing the visceral aortic segment. This is
indeed a significant contribution to demonstrate the feasibility of
this alternative approach to the open operation from which no
doubt many patients have benefited. It is notable that you have
been able to demonstrate that the endovascular procedure can be
carried out in many cases under regional anesthesia.
A few questions. It is a shame that this study could not have
been carried out alongside controls, particularly in view of the fact
that the data provided regarding the Gore TAG graft is such that at
2 years, there was no demonstrated difference in the survival rates.
Additionally, I would like for you to comment on your postoper-
ative anticoagulation regimen for these patients, and if you could,
explain to us why you would not recommend the use of cerebro-
spinal fluid drainage in all of your patients? Because 2 of your
spinal cord problems postoperatively were delayed, would you
recommend the insertion of a cerebrospinal fluid catheter in such
cases? And then, regarding this particular innovative technology,
would you comment, based upon your experience, on the require-
ments for the training and qualifications for the implementation of
such therapy?
Again, congratulations.
Dr Eric E. Roselli (Cleveland, Ohio). Thanks, Dr Coselli. With
regard to controls, I agree, it would be nice to compare controls to
these investigational patients. However, this is a technology that is
still in the process of evolution, and currently we are using this
selectively in patients who we don’t think have a good open
surgical alternative.
Our postoperative anticoagulation regimen in these patients is
not based at all on the procedure, although they are anticoagulated
during the procedure. Activated clotting time is maintained above
300 throughout the procedure, but then heparin is allowed to drift
or is reversed with protamine in the operating room. Otherwise
they receive antiplatelet therapy for concomitant coronary disease
or other comorbid indications.
Cerebrospinal fluid drainage was not used in all patients. The
patients that we used drainage for were at anatomic risk. So most
type 1, 2, and 3 thoracoabdominal aneurysms did have drainage
catheters, and also patients with type 4 aneurysms who had had
previous aortic surgery—who we felt to be at an elevated risk. The
2 patients who had paraplegia did have drainage catheters in place,
and unfortunately that wasn’t enough to prevent them from having
spinal cord ischemia. What we have learned, however, is that we
may be able to predict the patients who are going to be at the
highest risk based on their anatomy. Not all patients are selected
for this procedure if we believe they are at too high risk for spinal
cord injury. For example, a patient who has compromised internal
iliac perfusion who is going to require coverage of their subclavian
artery and extensive aortic coverage may not be recommended for
this procedure. If those important collateral vascular beds are
going to be compromised from this procedure, we will find another
way to deal with them—that is, with an internal iliac branch as an
additional part of the device or with a preoperative carotid sub-
clavian bypass.
And then, with regard to the question of the requirements for
training, these procedures require not only the ability to perform
complicated large-bore vascular access techniques such as con-
duits but also other extra-anatomic bypasses such as a carotid
subclavian bypass. Also, familiarity with complicated endovascu-
lar techniques, such as thrombolysis and embolization, and also the
know-how to deal with all of the branches of the viscera and the
aortic arch endovascularly are critical to a successful outcome.
Dr G. Wheatley (Phoenix, Ariz). Dr Roselli, I would like to
compliment you on an excellent study and excellent presentation,
and I would also like to compliment your colleagues and yourself
on moving this field forward.
I have two questions. The first is related to the number of
patients who underwent an open thoracoabdominal approach dur-
ing the same period of this study, just to get a sense of how many
patients were involved and whether or not the selection criteria
determined who got in each study in terms of whether it was an
endovascular requirement or were there other factors to determine
who was selected?
My second question is, Could you elaborate a little bit more on
the intense imaging in terms of 3-D reconstruction and mapping?
I think that is one important component to the success of this
procedure.
Dr Roselli. Thanks, Grayson. I don’t know the exact number of
patients, but I believe we have done over 100 open thoracoab-
dominal aneurysm repairs during this period. And you are exactly
right about the importance of 3-D imaging. I didn’t have time to
talk about the planning of these devices, but it is very intensive.
We do all the planning ourselves with the use of 3-D work stations,
and it is important to be very facile with that. I should add that to
the answer to Dr Coselli’s second question.
Dr C. Miller (Stanford, Calif). Dr Roselli and his colleagues
have shared with us some unbelievable technical wizardry today,
which is most impressive. My question pertains to why an inter-
vention was deemed necessary in these very old and very sick
patients. Some of us who have been around awhile have learned
the hard way in dealing with patients with thoracoabdominal
aneurysms that if you tamper with the work of the Lord too often,
you are going to get caught occasionally and things will not go
well. You didn’t tell us, Eric, or perhaps I missed it, what was the
clinical indication mandating a procedure in these individuals who
are old and trying to die from so many other diseases? It appears
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to me more and more that in this country one can’t die with dignity
anymore.
Dr Roselli. All right. Thanks, Dr Miller. You are right, these
patients are sick and old; however, the indication for therapy in
these patients was that they were at high risk from dying from their
aneurysms. And as shown in the data, for the patients with type 1,
2, and 3 aneurysms, the mean aneurysm size was nearly 8 cm. We
don’t treat every single high-risk patient with an intervention;
some patients are selected to be treated medically, but I don’t have
the data on the medically treated patients to make a comparison.
Dr. Miller. My question had more to do with symptoms, not
just size, justifying a prophylactic operation in an asymptomatic
individual. If these patients are symptomatic and presenting with
pain, then sure, one probably ought to intervene; conversely, in
asymptomatic very elderly patients with a large thoracoabdominal
aneurysm who have multiple comorbidities and little quality of life
left, I am not sure we should do anything except keep them
comfortable.
Dr. Roselli. Well, that is an interesting question, but we do
have over 80% survival at 1 year in these folks with large aneu-
rysms and no late aneurysm-related deaths. To answer your ques-
tion, though, no, these patients were not symptomatic. Symptom-
atic patients, unfortunately, are not candidates for this approach
because there is an inherent delay in the design and construction of
the device.
Dr S. Mitchell (Stanford, Calif). Great presentation and bold
work. The question, I may have missed it, were there any left
subclavian arteries covered during these repairs?
Dr Roselli. There was 1, and that patient did have a carotid
subclavian bypass beforehand.
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